In early February 2026, Omnicell reported fourth-quarter 2025 revenue of US$313.98 million with a small net loss of US$2.03 million, and issued first-quarter 2026 revenue guidance of US$300 million to ...
Omnicell’s fourth quarter was met with a significant negative market reaction, as the company delivered revenue in line with Wall Street expectations but posted a notable shortfall in non-GAAP ...
Omnicell, Inc. engages in the provision of medication management automation solutions and adherence tools for healthcare systems and pharmacies. Its solutions include intelligence, platform and ...